PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial hypercholesterolemia (FH ...

ASO: Antisense oligonucleotide; CHD: Coronary heart disease; HDL-C: HDL-cholesterol; HeFH: Heterozygous familial hypercholesterolemia ... Inhibition of PCSK9 at the mRNA or protein levels is ...

High cholesterol levels lead to plaque formation in arteries that restrict blood and oxygen flow. Familial ...

single-course solution for tackling high cholesterol levels. “Statins and PCSK9 inhibitors are phenomenal meds and we have so much evidence that they can reduce risk, but we see a huge gap in ...

PCSK9 mutations can either activate or inactivate its action, raising or lowering plasma LDL levels and coronary heart ...

Familial hypercholesterolemia (FH ... novel treatments like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These new therapies can help achieve LDL-C goals more effectively ...

Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...

A variant of PCSK9, a gene involved in raising cholesterol, may spur metastasis. An approved antibody might stop it.

et al.PCSK9 monoclonal antibody recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): a multicenter, randomized, double-blind, placebo-controlled phase 3 study. Presented at ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780 ... therapy in treatment-naive participants with high cholesterol (hypercholesterolaemia).

PCSK9 Program: Initial Data for the Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 Expected in the Second Quarter of 2025: VERVE-102, a novel, investigational base editing medicine targeting ...